Turner, N. C., Mayer, E. L., Park, Y. H., Janni, W., Ma, C., Cristofanilli, M., . . . Dalenc, F. (2026). Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): Extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncology, 27(8), 941-959.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Turner, Nicholas C., et al. "Switching to Camizestrant at ESR1 Mutation Emergence Before Disease Progression During First-line Treatment of Hormone Receptor-positive Advanced Breast Cancer (SERENA-6): Extended Analysis of a Double-blind, Placebo-controlled, Randomised, Phase 3 Trial."
Lancet Oncology 27, no. 8 (2026): 941-959.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Turner, Nicholas C., et al. "Switching to Camizestrant at ESR1 Mutation Emergence Before Disease Progression During First-line Treatment of Hormone Receptor-positive Advanced Breast Cancer (SERENA-6): Extended Analysis of a Double-blind, Placebo-controlled, Randomised, Phase 3 Trial."
Lancet Oncology, vol. 27, no. 8, 2026, pp. 941-959.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.